Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-1399
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Spotlight on Cabozantinib for Previously Untreated Advanced Renal Cell Carcinoma: Evidence to Date

Cancer Management and Research
Oncology
2018English

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2016English

Rationale for Targeted Therapies and Potential Role of Pazopanib in Advanced Renal Cell Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma in Adults Following Prior Vascular Endothelial Growth Factor Targeted Therapy: Clinical Trial Evidence and Experience

Therapeutic Advances in Urology
Urology
2018English

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives

Cancers
Cancer ResearchOncology
2011English

Potential Roles for PD‐1 and Cabozantinib in Patients With Metastatic Non‐Clear Cell Renal Cell Carcinoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Clinical Experience With Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2015English

Future Perspectives for Personalized Immunotherapy in Renal Cell Carcinoma

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2017English

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy